Nektar Therapeutics Stock Price (NASDAQ:NKTR)

Add to My Stocks
$13.7 $0.25 (1.86%) NKTR stock closing price Feb 27, 2017 (Closing)
Nektar Therapeutics
27 FEB 2017
amigobulls logo
NKTR hand_up
NKTR vs S&P 500
Closing Price: Feb 27, 2017
$13.7 ( 1.86%)
S&P 500
2369.8 ( 0.1%)
52 Week Price Range
1 Year Return: 20.41%
Q3 Growth*
Profitable ?
net image
2016 Q3 Net Loss
home image
☆ ☆ ☆ ☆ ☆★ ★ ★ ★ ★
Double Tap To Exit Full Screen

Nektar Therapeutics Snapshot Video

10 5 2

NKTR Stock Details

Prev Close* : $13.45
Market Cap:
Day Low: $13.34
52 Week Low: $10.67
Open: $13.4
Volume: 1620782
Day High: $13.79
52 Week High: $19.98

Latest Stock Market News

Latest Articles

Nektar Therapeutics News - From Partners

NKTR Stockcharts

View NKTR PE ratio, PS ratio stocks charts and compare with peers.
NKTR Chart
Note: Compare Nektar Therapeutics stock price history with the index and industry peers.

Nektar Therapeutics Valuation

PS ratio (
price to sales ratio

Nektar Therapeutics Financial Ratios

Asset Turnover
Receivables Turnover

NKTR Industry Peers

Company Price Change (%)
Ironwood Pharma (IRWD)16.770.35 (2.13%)
Zs Pharma (ZSPH)89.980 (0%)
Pfizer (PFE)34.280.02 (0.06%)
Progenics Pharma (PGNX)11.220.86 (8.3%)
Roche Holdings (RHHBY)30.330.27 (0.88%)
Bayer Ag (BAYRY)110.580.16 (0.14%)
Merck (MRK)65.850.31 (0.47%)

Top Stock Gainers

show top losers
CompanyPriceChange (%)
La Jolla Pharma (LJPC)35.1215.25 (76.75%)
ImmunoGen (IMGN)3.280.57 (21.03%)
Karyopharm Therapeutics (KPTI)11.131.03 (10.2%)
Arrowhead Pharma (ARWR)2.360.21 (9.77%)
Rigel Pharma (RIGL)2.520.22 (9.57%)
Heron Therapeutics (HRTX)15.151.25 (8.99%)
Xencor (XNCR)24.771.97 (8.64%)
Top gainers from Medical-Drugs industry
* As of Feb 28, 2017
CompanyPriceChange (%)
Merus Labs International (MSLI)0.840.02 (2.33%)
Lannett Co (LCI)22.60.3 (1.31%)
Redhill Biopharma (RDHL)9.320.11 (1.17%)
MADRIGAL PHARMA (MDGL)15.60.05 (0.32%)
Grifols (GRFS)17.480.02 (0.11%)
Zoetis (ZTS)53.830.05 (0.09%)
Top losers from Medical-Drugs industry
* As of Feb 28, 2017

Nektar Therapeutics Financial Statements

income statement20152014201320122011
Net Sales Or Revenues230.78M200.7M148.92M81.19M71.48M
Net Income-81.17M-53.91M-162.01M-171.85M-133.97M
Total Operating Expense226.04M188.65M230.54M191.95M173.52M
view Nektar Therapeutics income statement
balance sheet20152014201320122011
Total Assets502.06M441.62M434.52M497.79M606.55M
Total Liabilities495.63M405.28M524.43M450.77M408.73M
Shareholders Equity6.42M36.33M-89.9M47.01M197.81M
view Nektar Therapeutics balance sheet
cash flow statement20152014201320122011
Net Increase (Decrease) In Assets Liabilities-34.7M-116.42M90.58M1.6M-14.95M
Net Cash From (Used By) Operating Activities-73.08M-142M-38.52M-129.75M-113.74M
Increase (Decrease) In Prop Plant And Equipment-11.19M-9.97M-4.09M-10.58M-9.72M
view Nektar Therapeutics cashflow statement

Nektar Therapeutics Stock News - Partner Headlines

Weekly CEO sells highlight   on Sep 27, 2015

Nektar Therapeutics Stock Message Board

An investor needs to spend 13.7 to buy NKTR stock, as the closing Nektar Therapeutics stock price is 13.7. The total market value as denoted by 2.06B for Nektar Therapeutics, is the market value of the company's outstanding shares. Investors can use valuation multiples like the P/E ratio, price to sales ratio etc. for performing Nektar Therapeutics stock analysis.

The stock price movement of a company indicates what investors are willing to pay. For Ex: if investors feel that Nektar Therapeutics is worth a lot, it will most likely be reflected in an inflated Nektar Therapeutics stock quote, and vice versa. However, it must be noted that a company's value must not be equated to its share price. 1620782 shares were traded with a closing stock price of 13.7 as of 27 Feb, 2017, as can be seen from Nektar Therapeutics stock quote. One can view Nektar Therapeutics stock chart to follow the stock price trend. The board of directors decide what percentage of a company's earnings will be paid out as dividends. Nektar Therapeutics stock price history, gives the entire historical data for NKTR stock.